- Home
- MRNA vs JAZZ Comparison
MRNA vs JAZZ Comparison
Compare MRNA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | JAZZ |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.4B |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MRNA | JAZZ |
|---|---|---|
| Price | $55.54 | $186.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $33.00 | ★ $216.00 |
| AVG Volume (30 Days) | ★ 9.6M | 981.1K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $8.28 | $6.17 |
| Revenue Next Year | $16.53 | $7.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $95.49 |
| 52 Week High | $59.55 | $198.00 |
Technical Indicators
Market Signals| Indicator | MRNA | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 60.27 |
| Support Level | $23.74 | $159.78 |
| Resistance Level | N/A | $198.00 |
| Average True Range (ATR) | 3.84 | 6.03 |
| MACD | 0.26 | 0.40 |
| Stochastic Oscillator | 69.97 | 60.86 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.